MAPT and Alzheimer disease: Phosphorylated-tau immunohistochemistry in non-AD and AD brains was comparable to previous reports42 and is shown in Fig. 2B. The overall level of immunoreactivity in AD samples was much higher (Fig. 2B, right panel).